[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606691":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":31,"responsibleParty":72,"collaborators":11,"id":74,"slug":11,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":11,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Centre Jean Perrin","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"cDNA detection","EXPERIMENTAL",null,[13],"Biological: blood sampling",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"BIOLOGICAL","blood sampling","The intervention consist in blood samples (18mL) collected 1 and 3-months after the end of chemoradiotherapy",[9],[21],{"name":22,"affiliation":5,"role":23},"Maureen BERNADACH Coordinator, MD","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":29,"email":30},"Angeline GINZAC COUVÉ Project manager, PhD","CONTACT","0463663337","+33","angeline.ginzac@clermont.unicancer.fr",[32,50,61],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Centre Jean PERRIN","RECRUITING","Clermont-Ferrand","Puy-de-Dôme","63011","France",{"type":40,"coordinates":41},"Point",[42,43],3.08682,45.77969,{"lat":43,"lon":42},[46,48],{"name":47,"role":27,"phone":28,"phoneExt":29,"email":30},"Angeline GINZAC Project manager, PhD",{"name":22,"role":49,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"facility":51,"status":34,"city":52,"state":11,"zip":11,"country":38,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"Hôpital de la Croix-Rousse","Lyon",{"type":40,"coordinates":54},[55,56],4.84789,45.74906,{"lat":56,"lon":55},[59],{"name":60,"role":49,"phone":11,"phoneExt":11,"email":11},"Philippe CÉRUSE, Pr",{"facility":62,"status":34,"city":63,"state":11,"zip":11,"country":38,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"CHU de Saint-Étienne","Saint-Etienne",{"type":40,"coordinates":65},[66,67],4.39,45.43389,{"lat":67,"lon":66},[70],{"name":71,"role":49,"phone":11,"phoneExt":11,"email":11},"Yann LELONGE, Dr",{"type":73,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100606691",false,"NCT07178847","cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas","Evaluation of Circulating DNA as a Biomarker of Residual Disease After Chemoradiotherapy for Locally Advanced Head and Necksquamous Cell Carcinoma","NeckTAR-IN","Selection Criteria:\n\n* Patient included in NeckTAR study\n* Written informed consent signed for NeckTAR-IN study\n* Affiliation to the French social security system","ALL","18 Years","80 Years",{"count":85,"type":86},59,"ESTIMATED","INTERVENTIONAL",[89],"NA","The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma.\n\nThe main question it aims to answer is :\n\n\\- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological).\n\nParticipants will :\n\n* be included in the main study (Neck-TAR)\n* have a blood sample 1 and 3-month after the end of treatment",[92],"Locally Advanced Head and Neck Carcinoma",[94,95],"circulating DNA","residual disease","2026-06-01",{"date":98,"type":99},"2026-06-03","ACTUAL",{"date":101,"type":99},"2025-10-13",{"date":103,"type":86},"2031-07",{"name":5,"class":6},3]